Special ArticlesThe risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada1☆,
Section snippets
United Kingdom
A commercial vendor (Value Added Medical Products) provides hardware and software to general practitioners throughout the UK for computerizing patient record-keeping and office functions. To obtain this system at a reduced cost, many physicians agreed to record information in a standardized manner and to provide the information for research purposes. The resulting data, the General Practice Research Database, is now held by Britain’s Office of National Statistics, which permits analyses of
Results
During the study period, there were 18,571 eligible cisapride users in the UK and 18,172 in Saskatchewan. The study sample in the UK was somewhat younger than in Saskatchewan. In the UK, the median age at first cisapride use was 55 years; in Saskatchewan, the median age was 60 years. The most frequently used comparison drugs were ranitidine, omeprazole, cimetidine, and metoclopramide (Table 1).
Discussion
The cohort and case-control analyses from both the UK and Canada are consistent with an absence of any cisapride-induced increase in rates of arrhythmic events, at least under the conditions of cisapride usage that were prevalent in the first half of this decade. However, the upper confidence bounds for the relative risk of arrythmic events associated with cisapride use do not rule out a threefold to fourfold increase in risk. Thus, our results cannot rule out an increase in risk of that
References (15)
Physician’s Desk Reference
(1996)- Gerald K. McEvoy. Miscellaneous drugs. In: Gerald K. McEvoy, ed. American Hospital Formulary Service Drug Information...
- et al.
A comparison of two cohort studies evaluating the safety of cisaprideprescription-event mon-itoring and a large phase IV study
Eur J Clin Pharmacol
(1997) - et al.
Long QT syndrome during high-dose cisapride
Arch Intern Med
(1995) - et al.
Cisapride and fatal arrhythmia
NEJM
(1996) A Major Resource for Drug Safety StudiesThe General Practice Research Data Base
(1994)- Perry J, ed. OXMIS Problem Codes for Primary Medical Care. Oxford:...
Cited by (89)
Neurogenic Bowel
2018, Essentials of Physical Medicine and Rehabilitation: Musculoskeletal Disorders, Pain, and RehabilitationRosuvastatin blocks hERG current and prolongs cardiac repolarization
2012, Journal of Pharmaceutical SciencesCitation Excerpt :Finally, well-designed mechanistic studies are often the best way to identify drugs associated with LQTS. For instance, in the case of cisapride, Walker et al.44 reviewed the use of cisapride in 36,743 patients and could not find any link between cisapride use and LQTS; the odds ratio for cisapride use and cardiac outcomes was 1 (95% CI 0.3–3.7). However, at the same time, mechanistic in vitro (patch clamp) studies, ex vivo studies (explanted hearts), in vivo animal models, and case reports in patients were all pointing toward the conclusion that cisapride use is associated with an increased risk of drug-induced LQTS and death in certain patients.15
Drug-induced Sudden Death: A Scoping Review
2023, Current Drug SafetyCardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias
2018, Neurogastroenterology and MotilityMetoclopramide as intermittent and continuous infusions in critically ill patients: A pilot randomized clinical trial
2017, Journal of Comparative Effectiveness ResearchBridging the boundaries between scientists and clinicians—mechanistic hypotheses and patient stories in risk assessment of drugs
2017, Journal of Evaluation in Clinical Practice
- ☆
The research was supported by Janssen Pharmaceutica Research Foundation, Titusville, NJ, under a contract that guaranteed the authors unrestricted right of publication. Janssen is the manufacturer of cisapride. One of the authors, Chuen L. Yee, works for the R.W. Johnson Pharmaceutical Research Institute, which (like Janssen) is owned by Johnson & Johnson. Dr. Walker has served as a consultant to Janssen on issues of drug safety. None of the authors has a financial interest that relates to the outcome of this study.
- 1
This study is based in part on data provided by the Saskatchewan Department of Health. The interpretation and conclusions contained herein do not necessarily represent those of the Government of Saskatchewan or the Saskatchewan Department of Health.